Twice-daily application of ruxolitinib cream demonstrated an ability to reduce itching and blistering in prurigo nodularis, a ...
Hosted on MSN11mon
Essential Pharma acquires Reminyl from Janssen PharmaceuticaSpeciality pharmaceutical group Essential Pharma has concluded the acquisition of Reminyl oral capsules from the Johnson & Johnson company, Janssen Pharmaceutica. The strategic move enhances ...
Protagonist Therapeutics, Inc.'s VERIFY and ANTHEM-UC studies show breakthroughs in polycythemia vera and ulcerative colitis.
All the latest breaking news on United States. Browse ibtimes archives of photos, videos and articles on United States.
Johnson & Johnson subsidiary Janssen Pharmaceutica has licensed a range of drug candidates to BenevolentAI, a UK-based artificial intelligence company. The deal will make use of BenevolentAI’s ...
Four biosimilars for Stelara have launched in the United States this year following legal settlements with the reference ...
By analyzing genes encoding B-cell and T-cell receptors, the model could screen for conditions like HIV, type 1 diabetes, and ...
Contineum Therapeutics has concluded the targeted enrolment of 168 subjects in its Phase II trial of M1 receptor antagonist PIPE-307 to treat relapsing-remitting multiple sclerosis (RRMS).
5d
MedPage Today on MSNTopical JAK Inhibitor Active in Itchy Prurigo NodularisORLANDO -- More than 40% of patients with longstanding prurigo nodularis (PN) had significant improvement within 3 months of ...
This sentiment is echoed by Martin Price, Vice President for Health Economics, Market Access and Reimbursement EMEA at the Janssen Pharmaceutical Companies of Johnson & Johnson. “The system we ...
Patients treated with ESK-001 for moderate to severe plaque psoriasis experienced positive clinical responses through a year, ...
Pfizer Supercharges Obesity Battle with Top J&J Exec ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results